default author photo

Aryse Melo

National Institute of Health Doutor Ricardo Jorge

Lisbon

Portugal

SCHOLARLY PAPERS

2

DOWNLOADS

242

TOTAL CITATIONS

2

Scholarly Papers (2)

1.

Effectiveness of Covid-19 Vaccines Administered in the 2023 Autumnal Campaigns in Europe: Results from the Vebis Primary Care Test-Negative Design Study, September 2023–January 2024

Number of pages: 27 Posted: 01 May 2024
Epiconcept, National Institute of Health Doutor Ricardo Jorge, Epiconcept, Carlos III Institute of Health - Communicable Diseases Department, Robert Koch Institute, Health Service Executive, Semmelweis University, Sorbonne University - Institut Pierre Louis d'Épidémiologie et de Santé Publique IPLESP, National Health Institute Doutor Ricardo Jorge (INSA) - Epidemiology Department, Universidad Pública de Navarra - IdiSNA, Navarra Institute for Health Research, National Institute for Public Health and the Environment (RIVM) - Centre for Infectious Disease Control, Croatian Institute of Public Health, Public Health Agency of Sweden, Romanian Institute of Science and Technology - National Institute of Research and Development for Microbiology and Immunology „Cantacuzino”, Carlos III Health Institute, Robert Koch Institute, University College Dublin (UCD), Semmelweis University, University of Paris-Saclay - Laboratoire de Microbiologie, National Health Institute Doutor Ricardo Jorge (INSA) - National Influenza Reference Laboratory, Instituto de Salud Pública y Laboral de Navarra, NIVEL (Netherlands Institute for Health Services Research), Croatian Institute of Public Health, Public Health Agency of Sweden, National Institute for Public Health and the Environment (RIVM), National Health Institute Doutor Ricardo Jorge (INSA) - Bioinformatics Unit, Consejería de Sanidad, European Centre for Disease Prevention and Control, European Centre for Disease Prevention and Control and Epiconcept
Downloads 137 (534,155)
Citation 2

Abstract:

Loading...

COVID-19, vaccine effectiveness, multicentre study, test-negative design, Europe, SARS-CoV-2

2.

Effectiveness of XBB.1.5 Vaccines against Symptomatic SARS-CoV-2 Infection in Older Adults during the JN.1 Lineage-Predominant Period, European VEBIS Primary Care Multicentre Study, 20 November 2023–1 March 2024

Number of pages: 17 Posted: 11 Jul 2024
Epiconcept - Epidemiology Department, Epiconcept, National Health Institute Doutor Ricardo Jorge (INSA) - Epidemiology Department, Carlos III Institute of Health, Health Protection Surveillance Centre (HPSC), Sorbonne University - Institut Pierre Louis d'Épidémiologie et de Santé Publique IPLESP, Universidad Pública de Navarra - IdiSNA, Navarra Institute for Health Research, Robert Koch Institute, NIVEL (Netherlands Institute for Health Services Research), National Health Institute Doutor Ricardo Jorge (INSA) - Epidemiology Department, Semmelweis University, Public Health Agency of Sweden, Croatian Institute of Public Health, Cantacuzino National Military Medical Institute for Research and Development, Epiconcept, Consejería de Sanidad - Dirección General de Salud Pública, University College Dublin (UCD), University of Paris-Saclay - Laboratoire de Microbiologie, Universidad Pública de Navarra - IdiSNA, Navarra Institute for Health Research, Robert Koch Institute, National Institute for Public Health and the Environment (RIVM) - Centre for Infectious Disease Control, National Institute of Health Doutor Ricardo Jorge, Semmelweis University, Public Health Agency of Sweden, Croatian Institute of Public Health, National Institute for Public Health and the Environment (RIVM), National Institute of Health Doutor Ricardo Jorge, European Centre for Disease Prevention and Control, European Centre for Disease Prevention and Control and Epiconcept
Downloads 105 (664,543)

Abstract:

Loading...

COVID-19, SARS-CoV-2, Vaccine effectiveness, Primary care, Case-control study, Test-negative design, Multi-country study